Company type
High-definition PCR technology which enhances the multiplexing capabilities on existing hardware.Funding rounds
Series C
( )
Investment to support the launch of ChromaCode’s multi-drug resistant bacteria panel, tick-borne pathogen panel, SARS-CoV-2 panel, and upper-respiratory-tract infection panel.
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Adjuvant Capital | Initial investment. | ||
|
Domain Associates LLC | Venture capital firm focused on life sciences companies. | Initial investment. | |
|
New Enterprise Associates Inc (NEA) | Global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. | Initial investment. | |
|
Northpond Ventures | Science-driven venture capital firm headquartered in Bethesda, Maryland. | Initial investment. |
Investment activity status
Active investor